Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)

Abstract

The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably a mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal. The invention furthermore relates to a vaccine comprising said active (immunostimulatory) composition, and to the use of said active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, particularly of non-small cell lung cancers (NSCLC), preferably selected from the three main sub-types squamous cell lung carcinoma, adenocarcinoma and large cell lung carcinoma, or of disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

1 - 24 . (canceled) 
     
     
         25 . An immunostimulatory composition comprising:
 i) at least a first RNA comprising a coding region encoding NY-ESO-1; and   ii) at least a second RNA comprising a coding region encoding MAGE-A3.   
     
     
         26 . The immunostimulatory composition of  claim 25 , wherein the first RNA and the second RNA comprise a 5′ and/or a 3′ UTR sequence. 
     
     
         27 . The immunostimulatory composition of  claim 25 , wherein the first RNA and the second RNA comprise a 5′ and a 3′ UTR sequence. 
     
     
         28 . The immunostimulatory composition of  claim 25 , wherein the first RNA and the second RNA comprise a 3′ Poly-A sequence of 10 to 200 nucleotides. 
     
     
         29 . The immunostimulatory composition of  claim 25 , wherein the first RNA and the second RNA comprise a 5′ Cap. 
     
     
         30 . The immunostimulatory composition of  claim 25 , wherein the first RNA and the second RNA are in complex with a cationic compound. 
     
     
         31 . The immunostimulatory composition of  claim 25 , wherein the cationic compound comprises cationic peptides. 
     
     
         32 . The immunostimulatory composition of  claim 25 , wherein the cationic compound comprises cationic lipids. 
     
     
         33 . The immunostimulatory composition of  claim 25 , wherein the G/C content of the coding region of the first RNA is increased compared to the G/C content of the coding region of the wild-type RNA encoding NY-ESO-1. 
     
     
         34 . The immunostimulatory composition of  claim 33 , wherein the coding region of the first RNA, encoding NY-ESO-1 is at least about 85% identical to the RNA sequence corresponding to SEQ ID NO: 21. 
     
     
         35 . The immunostimulatory composition of  claim 34 , wherein the coding region of the first RNA, encoding NY-ESO-1 is at least about 90% identical to the RNA sequence corresponding to SEQ ID NO: 21. 
     
     
         36 . The immunostimulatory composition of  claim 25 , wherein the G/C content of the coding region of the second RNA is increased compared to the G/C content of the coding region of the wild-type RNA encoding MAGE-A3. 
     
     
         37 . The immunostimulatory composition of  claim 36 , wherein the G/C content of the coding region of the second RNA is increased compared to the G/C content of the coding region of the wild-type RNA encoding MAGE-A3. 
     
     
         38 . The immunostimulatory composition of  claim 36 , wherein the coding region of the second RNA, encoding MAGE-A3 is at least about 85% identical to the RNA sequence corresponding to SEQ ID NO: 17. 
     
     
         39 . The immunostimulatory composition of  claim 38 , wherein the coding region of the second RNA, encoding MAGE-A3 is at least about 90% identical to the RNA sequence corresponding to SEQ ID NO: 17. 
     
     
         40 . The immunostimulatory composition of  claim 25 , further comprising at least one additional RNA encoding a tumor antigen. 
     
     
         41 . The immunostimulatory composition of  claim 25 , further comprising an adjuvant. 
     
     
         42 . A kit comprising:
 i) at least a first composition comprising a RNA encoding NY-ESO1; and   ii) at least a second composition comprising a RNA encoding MAGE-A3.   
     
     
         43 . A method of stimulating an anti-tumor immune response in a subject comprising administering an effective amount of an immunostimulatory composition of  claim 25  to the subject. 
     
     
         44 . The method of  claim 43 , wherein the subject has a cancer.